Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 2/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.50 |
| ▸ | PTAFR | P25105 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8082818 | 0.92 | FDPS (0.54) | CHRNA7FDPSTBXAS1PTAFRLTA4H | |
| SCHEMBL5059827 | 0.78 | CHRNA7 (0.47) | CHRNA7FDPSTBXAS1PTAFREPHX2 | |
| SCHEMBL5054779 | 0.77 | TBXAS1 (0.52) | CHRNA7FDPSTBXAS1PTAFREPHX2 | |
| SCHEMBL7641415 | 0.76 | TBXAS1 (0.54) | CHRNA7FDPSTBXAS1PTAFREPHX2 | |
| SCHEMBL8061328 | 0.74 | L3MBTL1 (0.40) | FDPSL3MBTL1 | |
| SCHEMBL7643801 | 0.74 | CYP1A2 (0.52) | — | |
| SCHEMBL7604392 | 0.73 | TBXAS1 (0.54) | CHRNA7TBXAS1PTAFR | |
| SCHEMBL5661023 | 0.73 | FDPS (0.62) | CHRNA7FDPSTBXAS1CYP2A6 | |
| SCHEMBL8199794 | 0.72 | TDP1 (0.71) | CHRNA7TBXAS1PTAFRCYP2A6TDP1 | |
| SCHEMBL8200325 | 0.72 | CYP2A6 (0.68) | CHRNA7TBXAS1CYP2A6TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |